FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:94-95 July 5, 2007 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

To the Editor: Trastuzumab-mediated cardiotoxicity was originally described in women with metastatic breast cancer. The incidence rates were 13% when the antibody was administered in combination with paclitaxel and 27% when it was administered with an anthracycline.¹ Cardiotoxicity rates of 1.7 to 4.1% have been reported in several subsequent trials of adjuvant trastuzumab.^2,3,4 However, the incidence of cardiotoxicity among a population of women treated outside of a clinical trial is not known.

In 2005, all women in British Columbia, Canada, with human epidermal growth factor receptor type 2 (HER2)–positive early-stage breast cancer were offered adjuvant trastuzumab either sequentially after their . . . [Full Text of this Article]

This article has been cited by other articles:

• Turner, N. C, Jones, A. L (2008). Management of breast cancer--Part II. BMJ 337: a540-a540 [Full Text]  
• Chen, M. H., Kerkela, R., Force, T. (2008). Mechanisms of Cardiac Dysfunction Associated With Tyrosine Kinase Inhibitor Cancer Therapeutics. Circulation 118: 84-95 [Full Text]  
• Montemurro, F., Redana, S., Valabrega, G., Martinello, R., Aglietta, M., Palmiero, R. (2008). Trastuzumab-Related Cardiotoxicity in the Herceptin Adjuvant Trial. JCO 26: 2052-2053 [Full Text]